<DOC>
	<DOCNO>NCT00644410</DOCNO>
	<brief_summary>It single centre , randomise control study effect NOGA-guided direct intramyocardial injection mesenchymal stromal cell development new myocardium blood vessel patient heart failure . Stem cell obtain bone marrow culture expand 6 - 8 week injected myocardium . The patient follow safety , clinical , MRI CT endpoints 1 year .</brief_summary>
	<brief_title>Autologous Mesenchymal Stromal Cell Therapy Heart Failure</brief_title>
	<detailed_description>The primary objective investigate regenerative capacity direct intra-myocardial injection mesenchymal stromal cell patient reduce left ventricular EF ( â‰¤45 % ) heart failure NYHA 2-3 . A total 60 patient enrol study randomise 2 : 1 cell placebo ( saline ) . The patient follow 12 month . The primary endpoint change leave ventricle end-systolic volume ( LVESV ) 6 month follow-up . The secondary endpoint change leave ventricular ejection fraction ( LVEF ) , end-diastolic volume end-systolic mass 6 month follow-up . Other secondary endpoint NYHA , CCS , Kansas City Cardiomyopathy Questionnaire ( KCCQ ) , 6 min walk test , major adverse event endpoint : all-causes death , cardiovascular death , hospitalization worsen heart failure MI 12 month follow-up .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>EF &lt; 45 % NYHA 2 3 Acute coronary syndrome within last 6 week . Pregnancy FEV1 &lt; 1.0 Cancer Any severe disease could interfere treatment outcome</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>heart failure</keyword>
	<keyword>stem cell</keyword>
	<keyword>mesenchymal stromal cell</keyword>
	<keyword>mesenchymal stem cell</keyword>
</DOC>